A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Inclusion Criteria:

1. Age ≥ 18 years (or legal adult age within country, whichever is older) at the timethat the Informed Consent Form (ICF) is signed

2. Histologically or cytologically confirmed cancer of one of the following types,refractory to or relapsed after at least 1 prior standard therapeutic regimen in theadvanced/metastatic setting, as specified below. If no standard of care therapiesexist for the participant, or the participant cannot tolerate or refuses standard ofcare anticancer therapy, the participant may be allowed to participate on the studyafter discussion between the investigator and Amgen medical monitor. Participantswho have not received all approved or standard treatments for their cancer must beinformed that these alternatives to receiving bemarituzumab are available prior toconsenting to participate in the trial.

• head and neck squamous cell carcinoma: ≥ 1 line of therapy

• triple-negative breast cancer: ≥ 2 lines of therapy

• Intrahepatic cholangiocarcinoma ≥ 1 line of therapy

• lung adenocarcinoma: at least platinum-based chemotherapy, checkpointinhibitor, and targeted therapy

• platinum resistant ovarian epithelial cell carcinoma, including fallopian tubecancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy

• endometrial adenocarcinoma: ≥ 1 line of therapy

• cervical carcinoma: ≥ 1 line of therapy

• other solid tumors: ≥ 1 line of therapy

3. Disease that is unresectable, locally advanced, or metastatic (not amenable tocurative therapy)

4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing

5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

7. Adequate organ function as determined per protocol.

Exclusion Criteria:

1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningealdisease.

2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small celllung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma

3. Impaired cardiac function or clinically significant cardiac disease including:unstable angina within 6 months prior to first dose of study treatment, acutemyocardial infarction ≥ 6 months prior to first dose of study treatment, New YorkHeart Association (NYHA) class II-IV congestive heart failure, uncontrolledhypertension (defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiringanti-arrhythmic therapy other than beta blockers or digoxin, active coronary arterydisease or corrected QT interval QTc ≥ 470

4. History of systemic disease or ophthalmologic disorders requiring chronic use ofophthalmic steroids

5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing

6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment

7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations,keratitis, or keratoconus, or other known abnormalities of the cornea that may posean increased risk of developing a corneal ulcer prior/concomitant therapy

8. Prior treatment with any investigational selective inhibitor of the fibroblastgrowth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumorindication).